Manufacturing Made Simple Podcast
Aug 28, 2026 · 11 min · 7 segments
For over 40 years, a protein called RAS was considered "undruggable" until this week. The FDA just approved the first-ever targeted therapy built specifically to block RAS, the mutation driving over…
Andrew CheungHost
The drug is called Durexanracib, sold under the brand name RasonQ, developed by Revolution Medicines.
It's approved for adults with metastatic pancreatic adenocarcinoma, the most common and most aggressive form of pancreatic cancer.
who've already been through at least one round of systemic therapy, or who aren't candidates for standard combination chemotherapy.
Researchers have known it drives tumor growth since the 1980s, and for just as long, RAS was considered essentially undruggable.
In the phase 3 trial that led to the approval, patients on duracin-racib lived a median of 13.2 months versus 6.7 months on standard chemotherapy, nearly doubling survival, with a 60% reduction in risk of death and meaningfully slower disease progression.
And it's a once-daily tablet, not an infusion, not a biologic-requiring cold-chain logistics, just a pillop.
The drug is called Durexanracib, sold under the brand name RasonQ, developed by Revolution Medicines.
It's approved for adults with metastatic pancreatic adenocarcinoma, the most common and most aggressive form of pancreatic cancer.
who've already been through at least one round of systemic therapy, or who aren't candidates for standard combination chemotherapy.
Researchers have known it drives tumor growth since the 1980s, and for just as long, RAS was considered essentially undruggable.
In the phase 3 trial that led to the approval, patients on duracin-racib lived a median of 13.2 months versus 6.7 months on standard chemotherapy, nearly doubling survival, with a 60% reduction in risk of death and meaningfully slower disease progression.
And it's a once-daily tablet, not an infusion, not a biologic-requiring cold-chain logistics, just a pillop.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
